Menactra (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 - New Market Report

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

Menactra (Meningococcal Groups A, C, Y, W-135 polysaccharide diphtheria toxoid conjugate vaccine) is the brand name for Sanofi's tetravalent conjugate vaccine sold in the US and Australia to protect children, adolescents, and adults against four serogroups of N. meningitidis that cause invasive meningococcal disease. In 2005, Menactra became the first conjugate vaccine to be approved in the US for those 11 to 55 years of age. Approval was expanded to those from two to 55 years of age in the US in 2007, and to those as young as nine months of age in 2011, and it was also licensed for use in Australia in 2011.

Scope

* Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Menactra including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Menactra for the top nine countries from 2012 to 2022.
* Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil

Full Report Details at
- http://www.fastmr.com/prod/666330_menactra_meningococcal_vaccines_forecast_and.aspx?afid=301

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Menactra performance
* Obtain sales forecast for Menactra from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- PharmaPoint: Meningococcal Vaccines - Australia Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - Germany Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - Italy Drug Forecast and Market Analysis to 2022